Anne Szarewski

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

Jorma Paavonen, Paulo Naud, Jorge Salmerón et al. · The Lancet · 2009 · 1.6K citations

As04-adjuvanted Vaccine, Gynecology, Oncogenic Hpv Types +16

Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Matti Lehtinen, Jorma Paavonen, Cosette M. Wheeler et al. · The Lancet Oncology · 2011 · 693 citations

Vaccination, Cervical Cancer Screening, Hpv-16/18 As04-adjuvanted Vaccine +14

Long term predictive values of cytology and human papillomavirus testing in cervical cancer screening: joint European cohort study

Joakim Dillner, Matejka Rebolj, Philippe Birembaut et al. · BMJ · 2008 · 627 citations · Full text

Management of women who test positive for high-risk types of human papillomavirus: the HART study

Jack Cuzick, Anne Szarewski, Heather Cubie et al. · The Lancet · 2003 · 502 citations

Cancer Detection, Human Papillomavirus Vaccines, Cancer Screening +10

Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial

Cosette M. Wheeler, Xavier Castellsagué, Suzanne M. Garland et al. · The Lancet Oncology · 2011 · 499 citations

Vaccination, Vaccine Safety, Cervical Cancer Screening +14